Athira pharma reports first quarter 2024 financial results and pipeline and business updates

Topline data from phase 2/3 lift-ad clinical trial of fosgonimeton as a potential treatment for mild-to-moderate alzheimer's disease expected in second half of 2024  submitted investigational new drug application to u.s. food and drug administration for ath-1105 for the treatment of amyotrophic lateral sclerosis; on track to dose subjects in a first-in-human study in second quarter of 2024 strong balance sheet to support innovative pipeline through key clinical inflection points bothell, wash., may 15, 2024 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended march 31, 2024, and provided recent pipeline and business updates.
ATHA Ratings Summary
ATHA Quant Ranking